<DOC>
	<DOCNO>NCT01963715</DOCNO>
	<brief_summary>This Phase 1 , first-in-human study determine recommend dose IMGN289 adult patient advance EGFR-positive tumor .</brief_summary>
	<brief_title>A Phase 1 Study IMGN289 Adult Patients With EGFR-positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Antibodies</mesh_term>
	<criteria>18 year old time consent Diagnosed solid tumor progress despite standard therapy standard effective curative option exist suitable EGFRpositive tumor expression Adequate blood organ function Must agree use contraception study 12 week last dose IMGN289 applicable Must willing able sign inform consent follow study schedule protocol requirement Other anticancer treatment study Symptomatic brain metastases Other clinically significant disease define protocol Chronic skin condition require prescribed oral intravenous treatment History severe rash require discontinuation prior EGFR target therapy Receiving therapeutic dos warfarin heparin anticoagulation Known diagnosis HIV active viral hepatitis Women pregnant breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>IMGN289</keyword>
	<keyword>Antibody Drug Conjugate</keyword>
	<keyword>antibody</keyword>
	<keyword>EGFR</keyword>
	<keyword>NSCLC</keyword>
	<keyword>SCCHN</keyword>
	<keyword>Head neck</keyword>
	<keyword>Squamous cell carcinoma</keyword>
	<keyword>Solid tumor</keyword>
	<keyword>Immunogen</keyword>
	<keyword>Lung</keyword>
	<keyword>Phase 1</keyword>
</DOC>